Caparica R - Search Results

1

Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy-a sub-analysis of the ALTTO study.

Nader-Marta G, Debien V, Eiger D, Tsourti Z, Caparica R, Kassapian M, Napoleone S, Hultsch S, Korde L, Wang Y, Chumsri S, Pritchard KI, Untch M, Bellet-Ezquerra M, Dornelles Rosa D, Moreno-Aspitia A, Piccart M, Dafni U, de Azambuja E. Nader-Marta G, et al. Among authors: caparica r. Br J Cancer. 2022 Nov;127(10):1799-1807. doi: 10.1038/s41416-022-01963-8. Epub 2022 Sep 1. Br J Cancer. 2022. PMID: 36050448 Free PMC article. Clinical Trial.

2

Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials.

Caparica R, Bruzzone M, Poggio F, Ceppi M, de Azambuja E, Lambertini M. Caparica R, et al. Breast Cancer Res Treat. 2019 Feb;174(1):27-37. doi: 10.1007/s10549-018-5055-9. Epub 2018 Nov 21. Breast Cancer Res Treat. 2019. PMID: 30465156

3

Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives.

Caparica R, Lambertini M, Pondé N, Fumagalli D, de Azambuja E, Piccart M. Caparica R, et al. Ther Adv Med Oncol. 2019 Feb 25;11:1758835919827714. doi: 10.1177/1758835919827714. eCollection 2019. Ther Adv Med Oncol. 2019. PMID: 30833989 Free PMC article. Review.

4

How I treat metastatic triple-negative breast cancer.

Caparica R, Lambertini M, de Azambuja E. Caparica R, et al. ESMO Open. 2019 May 13;4(Suppl 2):e000504. doi: 10.1136/esmoopen-2019-000504. eCollection 2019. ESMO Open. 2019. PMID: 31231572 Free PMC article. Review.

5

Systemic treatment of patients with early breast cancer: recent updates and state of the art.

Caparica R, Brandão M, Piccart M. Caparica R, et al. Breast. 2019 Nov;48 Suppl 1:S7-S20. doi: 10.1016/S0960-9776(19)31115-4. Breast. 2019. PMID: 31839166 Review.

6

Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors.

Brandão M, Caparica R, Eiger D, de Azambuja E. Brandão M, et al. Among authors: caparica r. Ann Oncol. 2019 Dec 1;30(Suppl_10):x27-x42. doi: 10.1093/annonc/mdz280. Ann Oncol. 2019. PMID: 31859350 Free PMC article. Review.

7

[No title available]

[No authors listed] [No authors listed] PMID: 31928692

8

What Is the Real Impact of Estrogen Receptor Status on the Prognosis and Treatment of HER2-Positive Early Breast Cancer?

Brandão M, Caparica R, Malorni L, Prat A, Carey LA, Piccart M. Brandão M, et al. Among authors: caparica r. Clin Cancer Res. 2020 Jun 15;26(12):2783-2788. doi: 10.1158/1078-0432.CCR-19-2612. Epub 2020 Feb 11. Clin Cancer Res. 2020. PMID: 32046997 Free PMC article.

9

Prognostic and Predictive Impact of Beta-2 Adrenergic Receptor Expression in HER2-Positive Breast Cancer.

Caparica R, Richard F, Brandão M, Awada A, Sotiriou C, de Azambuja E. Caparica R, et al. Clin Breast Cancer. 2020 Jun;20(3):262-273.e7. doi: 10.1016/j.clbc.2020.01.007. Epub 2020 Mar 4. Clin Breast Cancer. 2020. PMID: 32229175

10

Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors.

Franzoi MA, Vandeputte C, Eiger D, Caparica R, Brandão M, De Angelis C, Hendlisz A, Awada A, Piccart M, de Azambuja E. Franzoi MA, et al. Among authors: caparica r. Breast Cancer Res Treat. 2020 May;181(1):199-209. doi: 10.1007/s10549-020-05617-2. Epub 2020 Apr 3. Breast Cancer Res Treat. 2020. PMID: 32246377

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

36 results

Search Page